Biotech News
Tune Therapeutics Secures $175M Financing to Accelerate Epigenome Editing Pipeline
Tune Therapeutics, a leading epigenome editing company, has secured over $175 million in financing to further the development of its innovative therapies targeting chronic and common diseases. The funding round was led by prominent investors including New Enterprise Associates, Yosemite,
17 January 2025